Synapse

This month on Synapse

Bracing for Brexit – pharmaceuticals and medical devices regulation if there is "no deal"

Our European team of life sciences specialists discuss the guidance available from the European Commission, and national governments and regulatory agencies for pharmaceutical and medical devices regulation in the event of a no-deal Brexit.

Biosimilars webinar series – Recent developments in biosimilars settlements, market landscape and antitrust scrutiny

In this webinar, speakers from Taylor Wessing and Willkie Farr & Gallagher focus on key factors decision-makers need to be aware of when considering settlement.

SPC for darunavir considered invalid in Dutch preliminary relief proceedings

Judith Krens and Misja Boeken discuss a recent a request for a preliminary injunction based on the Dutch supplementary protection certificate for darunavir made to the District Court of the Hague.

Essentially biological processes and their products – what is patentable?

Paul England outlines the conflict between the EU Commission and the Enlarged Board of the EPO about whether the products of essentially biological processes are patentable.